ArticlePloS one2012
Drugs of last resort? The use of polymyxins and tigecycline at US Veterans Affairs medical centers, 2005-2010.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.Critical care (London, England) · 2017Pooled it
- Causes of polymyxin treatment failure and new derivatives to fill the gap.The Journal of antibiotics · 2022Review
- Colistin and Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Polymyxin B Pharmacodynamics in the Hollow-Fiber Infection Model: What You See May Not Be What You Get.Antimicrobial agents and chemotherapy · 2021Article
- BKC-2, a New BKC Variant Detected in MCR-9.1-Producing Enterobacter hormaechei subsp.Antimicrobial agents and chemotherapy · 2021Article
- Antimicrobial effects of syndiotactic polypeptides.Scientific reports · 2021Article
- The First Egyptian Report Showing the Co-Existence ofInfection and drug resistance · 2020Article
- Short Cationic Peptidomimetic Antimicrobials.Antibiotics (Basel, Switzerland) · 2019Review
- Semisynthetic Analogues of Anhydrotetracycline as Inhibitors of Tetracycline Destructase Enzymes.ACS infectious diseases · 2019Article
- A Porcine Wound Model ofAdvances in wound care · 2019Article
- Biosynthesis of Oxytetracycline byFood technology and biotechnology · 2017Review
- Antimicrobial resistance in India.Journal of pharmaceutical policy and practice · 2017Article
- Synergy between Colistin and the Signal Peptidase Inhibitor MD3 Is Dependent on the Mechanism of Colistin Resistance in Acinetobacter baumannii.Antimicrobial agents and chemotherapy · 2016Article
- Combination therapy with polymyxin B and netropsin against clinical isolates of multidrug-resistant Acinetobacter baumannii.Scientific reports · 2016Article
- Antimicrobial Stewardship in Long-Term Care Facilities: A Call to Action.Journal of the American Medical Directors Association · 2016Review
- Article
- In vitro evaluation of ciclopirox as an adjuvant for polymyxin B against gram-negative bacteria.The Journal of antibiotics · 2015Article
- Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.Diagnostic microbiology and infectious disease · 2013Review
- Biotic acts of antibiotics.Frontiers in microbiology · 2013Article
- Evolution in action: dissemination of tet(X) into pathogenic microbiota.Frontiers in microbiology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Multidrug-resistant (MDR) and carbapenem-resistant (CR) Gram-negative pathogens are becoming increasingly prevalent around the globe. Polymyxins and tigecycline are among the few antibiotics available to treat infections with these bacteria but little is known about the frequency of their use. We therefore aimed to estimate the parenteral use of these two drugs in Veterans Affairs medical centers (VAMCs) and to describe the pathogens associated with their administration. For this purpose we retrospectively analyzed barcode medication administration data of parenteral administrations of polymyxins and tigecycline in 127 acute-care VAMCs between October 2005 and September 2010. Overall, polymyxin and tigecycline use were relatively low at 0.8 days of therapy (DOT)/1000 patient days (PD) and 1.6 DOT/1000PD, respectively. Use varied widely across facilities, but increased overall during the study period. Eight facilities accounted for three-quarters of all polymyxin use. The same statistic for tigecycline use was twenty-six VAMCs. There were 1,081 MDR or CR isolates during 747 hospitalizations associated with polymyxin use (1.4/hospitalization). For tigecycline these number were slightly lower: 671 MDR or CR isolates during 500 hospitalizations (1.3/hospitalization) (p = 0.06). An ecological correlation between the two antibiotics and combined CR and MDR Gram-negative isolates per 1000PD during the study period was also observed (Pearson's correlation coefficient r = 0.55 polymyxin, r = 0.19 tigecycline). In summary, while polymyxin and tigecycline use is low in most VAMCs, there has been an increase over the study period. Polymyxin use in particular is associated with the presence of MDR Gram-negative pathogens and may be useful as a surveillance measure in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.